

Title (en)

REAGENTS AND METHODS FOR MODULATING DKK-MEDIATED INTERACTIONS

Title (de)

REAGENZIEN UND VERFAHREN ZUR MODULATION VON DKK-VERMITTELNEN WECHSELWIRKUNGEN

Title (fr)

REACTIFS ET PROCEDES DESTINES A MODULER DES INTERACTIONS INDUITES PAR DKK

Publication

EP 1395285 A4 20050601 (EN)

Application

EP 02744162 A 20020517

Priority

- US 0215982 W 20020517
- US 29131101 P 20010517
- US 35305802 P 20020201
- US 36129302 P 20020304

Abstract (en)

[origin: WO02092015A2] The present invention provides reagents, compounds, compositions, and methods relating to novel interactions of the extracellular domain of LRP5, HBM (a variant of LRP5), and/or LRP6 with Dkk, including Dkk-1. The various nucleic acids, polypeptides, antibodies, assay methods, diagnostic methods, and methods of treatment of the present invention are related to and impact on Dkk, LRP5, LRP6, HBM, and Wnt signaling. Dkk, LRP5, LRP6, HBM, and Wnt are implicated in bone and lipid cellular signaling. Thus, the present invention provides reagents and methods for modulating lipid levels and/or bone mass and is useful in the treatment and diagnosis of abnormal lipid levels and bone mass disorders, such as osteoporosis.

IPC 1-7

A61K 39/395; A61K 39/00; A61K 39/38

IPC 8 full level

A01K 67/027 (2006.01); **A61K 31/7105** (2006.01); **A61K 38/00** (2006.01); **A61K 39/395** (2006.01); **A61K 48/00** (2006.01); **A61P 3/06** (2006.01); **A61P 3/14** (2006.01); **A61P 17/00** (2006.01); **A61P 19/00** (2006.01); **A61P 19/02** (2006.01); **A61P 19/08** (2006.01); **A61P 19/10** (2006.01); **A61P 29/00** (2006.01); **A61P 43/00** (2006.01); **C07K 14/47** (2006.01); **C07K 14/51** (2006.01); **C07K 16/18** (2006.01); **C12N 15/09** (2006.01); **C12N 15/85** (2006.01); **C12Q 1/02** (2006.01); **G01N 33/15** (2006.01); **G01N 33/50** (2006.01); **G01N 33/92** (2006.01)

CPC (source: EP)

A61P 3/06 (2017.12); **A61P 3/14** (2017.12); **A61P 17/00** (2017.12); **A61P 19/00** (2017.12); **A61P 19/02** (2017.12); **A61P 19/08** (2017.12); **A61P 19/10** (2017.12); **A61P 29/00** (2017.12); **A61P 43/00** (2017.12); **C07K 14/51** (2013.01); **C12N 15/8509** (2013.01); **A01K 2207/15** (2013.01); **A01K 2217/00** (2013.01); **A01K 2217/05** (2013.01); **A01K 2217/075** (2013.01); **A01K 2227/50** (2013.01); **A01K 2267/03** (2013.01); **A01K 2267/0362** (2013.01); **A01K 2267/0393** (2013.01); **A61K 38/00** (2013.01)

Citation (search report)

- [X] WO 0052047 A2 20000908 - MILLENNIUM PHARM INC [US]
- [E] WO 02066509 A2 20020829 - GENENTECH INC [US]
- [A] GLINKA ET AL: "Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 391, no. 6665, 22 January 1998 (1998-01-22), pages 357 - 362, XP002096088, ISSN: 0028-0836
- [E] DATABASE WPI Section Ch Week 200312, Derwent World Patents Index; Class B04, AN 2003-129214, XP002304054
- See references of WO 02092015A2

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

WO 02092015 A2 20021121; WO 02092015 A3 20031023; AU 2002342734 B2 20070726; BR 0209836 A 20041207; CA 2446582 A1 20021121; EP 1395285 A2 20040310; EP 1395285 A4 20050601; IL 158750 A0 20040512; JP 2005512508 A 20050512; JP 2009142274 A 20090702

DOCDB simple family (application)

US 0215982 W 20020517; AU 2002342734 A 20020517; BR 0209836 A 20020517; CA 2446582 A 20020517; EP 02744162 A 20020517; IL 15875002 A 20020517; JP 2002588934 A 20020517; JP 2008302849 A 20081127